Last reviewed · How we verify

Thymoglobulin + Everolimus — Competitive Intelligence Brief

Thymoglobulin + Everolimus (Thymoglobulin + Everolimus) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressant. Area: Immunology.

phase 3 Immunosuppressant CD3 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Thymoglobulin + Everolimus (Thymoglobulin + Everolimus) — University Hospital, Brest. Thymoglobulin is an anti-CD3 monoclonal antibody that depletes T cells, while Everolimus is an mTOR inhibitor that suppresses cell proliferation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Thymoglobulin + Everolimus TARGET Thymoglobulin + Everolimus University Hospital, Brest phase 3 Immunosuppressant CD3
Talvey TALQUETAMAB Janssen Biotech marketed T-cell surface glycoprotein CD3 2023-01-01
Elrexfio Elranatamab Pfizer marketed Bispecific antibody BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells 2023-01-01
Epkinly EPCORITAMAB Genmab Us, Inc. marketed Bispecific CD20-directed CD3 T Cell Engager [EPC] T-cell surface glycoprotein CD3 2023-01-01
Elrexfio elranatamab Pfizer marketed Bispecific antibody BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells 2023-01-01
ELRANATAMAB ELRANATAMAB marketed BCMA, CD3 2023-01-01
Bcmaxcd3 TECLISTAMAB Johnson & Johnson marketed CD3, BCMA 2022-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressant class)

  1. Assistance Publique Hopitaux De Marseille · 1 drug in this class
  2. Centre Hospitalier Universitaire, Amiens · 1 drug in this class
  3. Hospices Civils de Lyon · 1 drug in this class
  4. I.M. Sechenov First Moscow State Medical University · 1 drug in this class
  5. Kenya Medical Research Institute · 1 drug in this class
  6. Memorial Sloan Kettering Cancer Center · 1 drug in this class
  7. National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class
  8. Peking Union Medical College Hospital · 1 drug in this class
  9. RWTH Aachen University · 1 drug in this class
  10. Samsung Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Thymoglobulin + Everolimus — Competitive Intelligence Brief. https://druglandscape.com/ci/thymoglobulin-everolimus. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: